BiotechTube

YM872 (zonampanel)

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cerebrovascular Accident

Conditions

Cerebrovascular Accident

Trial Timeline

Dec 1, 2000 → Jan 1, 2003

NCT ID
NCT00044070

About YM872 (zonampanel)

YM872 (zonampanel) is a phase 2 stage product being developed by Astellas Pharma for Cerebrovascular Accident. The current trial status is completed. This product is registered under clinical trial identifier NCT00044070. Target conditions include Cerebrovascular Accident.

What happened to similar drugs?

5 of 7 similar drugs in Cerebrovascular Accident were approved

Approved (5) Terminated (1) Active (1)
✅Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved
✅ticagrelor + ASA + Placebo+ASAAstraZenecaApproved
✅AtorvastatinPfizerApproved
✅Botulinum toxin type A + PlaceboIpsenApproved
✅Atorvastatin 20mgBrain BiotechApproved
🔄donepezil hclEisaiPhase 3
❌AbciximabEli LillyPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00044070Phase 2Completed

Competing Products

14 competing products in Cerebrovascular Accident

See all competitors
ProductCompanyStageHype Score
donepezil hclEisaiPhase 3
40
Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved
43
ONO-2506Ono PharmaceuticalPhase 2/3
30
AbciximabEli LillyPhase 3
32
atomoxetine + StimulantsEli LillyPre-clinical
26
ticagrelor + ASA + Placebo+ASAAstraZenecaApproved
43
ValsartanNovartisPre-clinical
18
AtorvastatinPfizerApproved
43
RivaroxabanBayerPre-clinical
19
Darolutamide (BAY1841788) + EnzalutamideBayerPhase 1
26
Botulinum toxin type A + PlaceboIpsenApproved
40
Atorvastatin 20mgBrain BiotechApproved
40
Autologous bone marrow mononuclear cell transplantationBrain BiotechPhase 1
11
Roflumilast Oral TabletBrain BiotechPhase 2
25